Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.

"We are thrilled to welcome Jeff to the Obsidian leadership team as the company's Chief Financial Officer," said Madan Jagasia, M.D., Chief Executive Officer of Obsidian. "Jeff brings a breadth of strategic, operational, and financial experience in the life sciences industry, including building and growing private and public biotechnology companies. His expertise will be crucial as the company moves into its next stage of growth and continues advancing the clinical development of Obsidian's lead engineered tumor-infiltrating lymphocyte (TIL) cell therapy, OBX-115."

"I am honored to join Obsidian at this pivotal time in the company's evolution," said Mr. Trigilio. "Obsidian has built a strong financial foundation with the support of top-tier life sciences investors and mutual funds. I am excited to join a leadership team with outstanding scientific and clinical development track records and help drive continued growth as we advance Obsidian's cytoDRiVE platform to develop novel engineered cell and gene therapies in areas of high unmet need."

Mr. Trigilio has served in a variety of financial and strategy roles in various life sciences and investment banking companies. Most recently, he served as Chief Financial Officer of Cullinan Oncology, where he guided its initial public offering and helped secure several business development transactions for its portfolio. Before Cullinan, Mr. Trigilio served as Chief Financial Officer for Amylyx Pharmaceuticals, Vice President of Corporate Finance at BlueRock Therapeutics, and in various corporate strategy and finance roles at Alexion Pharmaceuticals. Mr. Trigilio also has previous healthcare equity capital markets and investment banking experience at RBC Capital Markets and Credit Suisse. Mr. Trigilio holds an M.B.A. from Columbia Business School and a B.A. in Industrial and Labor Relations from Cornell University.

About OBX-115

Obsidian's lead investigational cytoTIL15tm program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian's proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. OBX-115 is being investigated in two ongoing and enrolling clinical trials in advanced or metastatic melanoma and NSCLC (NCT05470283 and NCT06060613).

About Obsidian Therapeutics

Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE^® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn.